IDEAYAIDYA
NASDAQPharmaceuticals
No cached AI snapshot yet for IDYA.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
145 employees87.81M shares outstandinglisted 2019-05-23
Next earnings ~May 5, 2026
About IDEAYA
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Latest News
Showing market-wide stock news
IDEAYA Biosciences, Inc. (IDYA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
IDEAYA Biosciences at Morgan Stanley conference: darovasertib leads push
Treasury ETF shorts shift toward belly ahead of Fed decision
BoE to 'stand ready to hike', committee remains 'deeply divided'
The Fed’s interest rate decision in the epicenter of attention
News Flash: 70% of Wall Street Institutions Are Calling for at Least a 50-Basis-Point Fed Rate Hike in 2026
Related Stocksin Pharmaceuticals
Ready to see the live AI view on IDYA?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing IDYA side-by-side with live signals.